BlogHeader.png

eBook: Analytical Testing in Drug Development

Abuse-deterrent iStock-687356630Alcami recently contributed to an eBook produced by Drug Development and Delivery. The eBook, titled "Analytical Testing in Drug Development," features four companies and explains how they each help the pharmaceutical and biotech industries comply with drug development regulatory requirements. 

Angela Moore, abuse-deterrence studies subject matter expert at Alcami, contributed to the eBook. Her article focuses on considerations for abuse-deterrent Category 1 studies as well as standard syringeability studies.

"Healthcare professionals around the world are commonly prescribing opioid medications for pain management, generating an inevitable association with abuse and addiction. The Centers for Disease Control and Prevention (CDC) has estimated that, in 2017, over 47,600 Americans died from opioid overdoses. Of these deaths, 35% involved the use of prescription opioid medications."

Read Full Article Here

MORE CONTENT RELATED TO ABUSE-DETERRENT STUDIES

Learn More About Alcami's Abuse-Deterrence Services

 

Ready to Get Started?

Connect with an Expert

 

Topics: Thought Leadership Regulatory Compliance Abuse-Deterrence Editorials Development